Results of clinical trials of PD-1 blockade have shown that the presence of tumor-infiltrating lymphocytes (TILs), and in particular, the number of CD8+ T cells, can be prognostic markers for clinical response for patients with NSCLC (6). This evidence concerns the gene PDCD1 and neoplasm.